Reimagining Medicine
Company overview
Financial review
Conclusions
Appendix
References
Key 2023 readouts for high-value medicines on track
INNOVATION
Key assets* with submission enabling readouts in 2023
KisqaliⓇ
Ph3 NATALEE trial in
adjuvant breast cancer
testing broad patient
population (anatomical
stage II and III1), further
Primary
endpoint
met at
interim
analysis
follow up data on track
for H2 2023
EMA and FDA regulatory submission
PluvictoⓇ
PSMAfore trial in mCRPC
(post-ARDT, pre-taxane) positive
readout; detailed data presentation
planned in Q4 2023
FDA regulatory submission
planned in Q4 2023
Iptacopan
PNH filed with FDA and EMA in Q2 2023
APPLAUSE-IgAN Ph3 readout²
planned in Q4 2023
APPEAR-C3G Ph3 readout
planned in Q4 2023
expected Q3/Q4 2023
*Unprobabilized peak sales of all asset indications in late-stage development: > USD 1bn
> USD 2bn
> USD 3bn
mCRPC metastatic castration resistant prostate cancer. ARDT-androgen receptor directed therapy. 1. Based on AJCC prognostic staging.
2. 9 months analysis potentially supporting US Subpart H filing.
15 Investor Relations | Q2 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation